[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Szeged University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":136},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,52,75,109],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100612239","pallas-laser-for-skin-diseases-100612239",false,"NCT07250997","PALLAS Laser for Skin Diseases","Study of the Effectiveness of the PALLAS Laser in the Treatment of Skin Diseases That Respond Well to UV Light","PALLAS-UV","Inclusion Criteria:\n\n1. The subject understands the information provided, gives informed consent to participate in the study and is deemed by the investigator to be able to participate,\n2. a skin condition that is expected to respond well to targeted UVB treatment,\n3. a signed consent form.\n\nExclusion Criteria:\n\n1. Patient under 18 years of age,\n2. pregnancy\n3. epilepsy,\n4. fever, infectious diseases,\n5. the patient is within one month or currently enrolled in another clinical trial.","ALL","18 Years","65 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","The primary objective of this study is to get clinical experiences with the PALLAS laser in the treatment of skin conditions that respond well to UV light (vitiligo, psoriasis, alopecia areata, atopic dermatitis).\n\nThe secondary objective is to assess how user-friendly is the Pallas laser in the treatment of skin diseases.\n\nThe patient in the trial will receive UVB laser treatment (2 treatments per week for up to 3 months). The treatments will be carried out by the doctors participating in the trial.\n\nThe treatment takes approximately 10 minutes per session, and can last up to 3 months per patient.\n\nPhotographic documentation of the lesions to be treated and the lesions treated is taken at the start of the examination and then once a month.\n\nAt the end of the study, the patient rates the treatment and improvement on a Patient Satisfaction Scale.",[28,29,30,31],"Vitiligo Vulgaris","Psoriasis","Alopecia Areata","Atopic Dermatitis",[33,34,35,36,37,38],"UVB laser treatment","PALLAS laser","vitiligo","psoriasis","alopecia areata","atopic dermatitis","RECRUITING","2026-02-05",{"date":42,"type":43},"2026-02-06","ACTUAL",{"date":45,"type":43},"2025-12-10",{"date":47,"type":22},"2026-12-31",{"name":49,"class":50},"Szeged University","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":19,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":74,"locationsCount":51},"100612235","advatx-laser-treatment-for-vascular-birthmarks-100612235","NCT07250945","AdvaTx Laser Treatment for Vascular Birthmarks","Study of the Effectiveness of the ADVATx Laser in the Treatment of Port-wine Stains","ADVA-PWS","Inclusion Criteria:\n\n1. The patient understands the information provided, gives informed consent to participate in the study and is deemed by the investigator to be able to participate,\n2. a signed consent form,\n3. parental consent is required for patients under 18 years of age,\n4. the lesions to be treated are at least 15 cm2,\n5. the study is open to Fitzpatrick skin types I-IV.\n\nExclusion Criteria:\n\n1. Lack of parental consent for patients under 18 years of age,\n2. symptoms localised to the central part of the face (cheeks, nose),\n3. people with Fitzpatrick skin type V-VI,\n4. pregnancy,\n\n4\\. epilepsy, 5. fever, infectious diseases, 6. the patient is within one month or currently enrolled in another clinical trial.","7 Years",{"count":62,"type":22},20,[25],"The primary objective of the present study is to get experiences with the use of CE-marked ADVATx laser treatment for port-wine stains.\n\nSecondary objectives: To investigate the clinical efficacy of ADVATx laser treatment for port-wine stains.\n\nTo investigate the potential side effects (erythema, hyperpigmentation, oedema, pain, swelling, skin burning, blisters) of the treatment.\n\nPatients in the study will receive ADVATx laser treatment (1 treatment per month for 4 months) The treatment takes approximately 10-30 minutes per session. The treatment lasts for a total of 5 months for one patient. At each treatment session photographic documentation will be performed. PRO will be assessed by a questionnaire. At the end of the study, the patient rates the treatment and improvement on a Patient Satisfaction Scale.",[66,67],"Port-wine Stains (PWS)","Vascular Birthmark",[69,70,67],"ADVATx laser","Port-wine stain",{"date":42,"type":43},{"date":45,"type":43},{"date":47,"type":22},{"name":49,"class":50},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":84,"minAge":18,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":97,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":51},"100587824","elastographic-assessment-of-suburethral-tissue-in-continent-and-incontinent-women-100587824","NCT06933407","Elastographic Assessment of Suburethral Tissue in Continent and Incontinent Women","This Study Investigates the Role of Strain Elastography in Assessing Paraurethral Tissue Elasticity in Continent and Incontinent Pre- and Postmenopausal Women. It Also Evaluates the Predictive Value of Strain Elastography Compared to Other Pelvic Imaging Modalities, Including Conventional Ultrasound Examinations, in Supporting Treatment Decision-making for Urinary Incontinence.","SE-inc1","Inclusion Criteria:\n\n* Clinical diagnosis of stress urinary incontinence (SUI) based on patient history, physical examination, and\u002For urodynamic assessment.\n\nExclusion Criteria:\n\n* Pelvic malignancy or history of pelvic radiation therapy\n* Urge urinary incontinence (UUI) or detrusor overactivity\n* Pelvic organ prolapse (POP) stage ≥ II (based on POP-Q classification)\n* Pregnancy or recent postpartum status (less than 6 months postpartum)\n* Neurological disorders affecting bladder function\n* Recurrent urinary tract infections (UTIs) or active lower urinary tract infection\n* Inability to undergo study procedures\n* Cognitive impairment or psychiatric conditions affecting informed consent or compliance",true,"FEMALE","99 Years",{"count":87,"type":22},80,"OBSERVATIONAL","Strain elastography (SE) will be utilized as a non-invasive imaging technique to evaluate tissue elasticity and biomechanical properties in women with stress urinary incontinence (SUI) and in continent controls. The primary aim is to determine whether SE can detect differences in paraurethral tissue stiffness between these groups. Given the established role of tissue elasticity in the pathophysiology of SUI, SE will be investigated as a potential diagnostic tool in urogynecological evaluations.\n\nThis prospective cohort study will be conducted at a tertiary referral center. All participants will undergo introital two-dimensional (2D) ultrasound in the midsagittal plane at rest. SE will be performed in three predefined suburethral regions of interest (ROIs):\n\n* internal urethral orifice (IUO) level\n* midurethra (MU) level\n* external urethral orifice (EUO) level\n\nThe adipose layer (AL) between the external urethral meatus and the pubic symphysis will serve as the reference tissue, representing the softest anatomical structure in the region.\n\nDescriptive and comparative statistical analyses will be conducted to assess differences in paraurethral tissue stiffness between the study groups.\n\nIt is hypothesized that SE will be able to detect differences in paraurethral tissue elasticity, with SUI being associated with increased tissue compliance. The study also aims to determine whether SE can reliably distinguish between varying degrees of tissue stiffness in women with SUI and continent controls.\n\nPathophysiological focus:\n\nThe study will explore key mechanisms underlying SUI, including:\n\n* Weakened bladder neck support\n* Impaired urethral stabilization due to increased tissue elasticity and collagen degradation\n* While conventional 2D ultrasound provides anatomical information, it does not directly evaluate tissue biomechanics. In contrast, SE enables real-time visualization of tissue elasticity, offering a promising adjunct to traditional urogynecological assessment methods.\n\nStandardization and Protocol\n\nThe study will follow a standardized protocol to ensure reproducibility and high-quality data. Key methodological elements include:\n\n* Minimal probe compression during introital ultrasound to avoid artifacts\n* Bladder emptying prior to examination to eliminate confounding effects\n* Carefully standardized ROI placement across all patients\n* Controlled image acquisition conditions to reduce variability\n\nFuture Directions\n\n* Future research based on this study will aim to:\n* Optimize SE protocols and refine ROI placement strategies\n* Establish clinical cutoff values for differentiating tissue stiffness in SUI vs. continent women\n* Assess the long-term effects of pelvic floor muscle training (PFMT) and vaginal estrogen therapy on paraurethral biomechanics\n* Facilitate the integration of SE into routine urogynecological practice to support early diagnosis and personalized treatment strategies for SUI",[91,92,93,94,95,96],"Urinary Incontinence","Urinary Incontinence, Stress","Urinary Incontinence (UI)","Urinary Bladder, Overactive","Incontinence, Overactive Bladder, Stress Urinary Incontinence","Stress Urinary Incontinence (SUI)",[91,98,99,100],"Bladder dysfunction","Urine leakage","Stress urinary incontinence (SUI)","2025-04-15",{"date":103,"type":43},"2025-04-18",{"date":105,"type":43},"2024-08-16",{"date":107,"type":22},"2030-01-01",{"name":49,"class":50},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":119,"briefSummary":120,"conditions":121,"keywords":124,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100436680","calcinosis-reduction-by-pyrophosphate-in-ssc-100436680","NCT04966416","Calcinosis Reduction by Pyrophosphate in SSC","The Effect of Orally Administered Pyrophosphate on Calcinosis Formation in Systematic Sclerosis","Inclusion Criteria:\n\n* to meet ACR\u002F EULAR classification criteria\n\nExclusion Criteria:\n\n* severe upper minfestation of SSC\n* hypo- or hyperthyreoidism\n* QT prolongation on ECG","70 Years",{"count":118,"type":22},60,[25],"Calcinosis, i.e. crystal-like nodules are troublesome complication of systemic sclerosis, an autoimmune disease. Pyrophosphate inhibits its formation is laborytory. We would like to test if orally administered pyrophosphate prevents calcinosis formation.",[122,123],"Systemic Sclerosis","Scleroderma",[125,126],"calcinosis","pyrophosphate","NOT_YET_RECRUITING","2023-05-23",{"date":130,"type":43},"2023-05-25",{"date":132,"type":22},"2023-08-01",{"date":134,"type":22},"2026-06-30",{"name":49,"class":50},""]